Cyberkinetics Neurotechnology Systems, Inc. (OTCBB:CYKN; “Cyberkinetics”) announced that Timothy R. Surgenor, Cyberkinetics' President and Chief Executive Officer, will present at the First Annual OneMedPlace (OMP) Finance Forum at 2:40 p.m. (PST) on Monday, January 7, 2008, at the Sir Francis Drake Hotel in San Francisco, California.
In his presentation, Mr. Surgenor will provide an update on Cyberkinetics’ strategy to develop the Andara™ OFS™ (Oscillating Field Stimulator) Therapy, which is designed to stimulate nerve growth and restore function following a nervous system injury. If the Company’s Humanitarian Device Exemption is approved by the Food and Drug Administration, the Andara™ OFS™ System could be the first commercially available neurotechnology device designed to partially restore sensation and motor function in acute spinal cord injuries.
An audiocast of Mr. Surgenor’s presentation will be available on Friday, January 11, 2008, at www.onemedplace.com. A copy of Cyberkinetics’ presentation will be available on January 7, 2008, at the Company’s website at www.cyberkinetics.com/content/aboutus/mediakit.jsp.
About Cyberkinetics Neurotechnology Systems, Inc.
Cyberkinetics Neurotechnology Systems, Inc., a leader in the neurotechnology industry, is developing neural stimulation, sensing and processing technology to improve the lives of those with severe paralysis resulting from spinal cord injuries, neurological disorders and other conditions of the nervous system. Cyberkinetics’ product development pipeline includes: Andara™ OFS™ Therapy for acute spinal cord injury, an investigative device designed to stimulate nerve repair and restore sensation and motor function; the BrainGate System, an investigative device designed to provide communication and control of a computer, assistive devices, and, ultimately, limb movement; and a pilot program in the detection and prediction of seizures due to epilepsy. Additional information is available at Cyberkinetics’ website at www.cyberkinetics.com.
Forward-Looking Statements
This announcement contains forward-looking statements, including statements about Cyberkinetics' product development plans and progress, potential development of proprietary inventions and benefits that may be realized by certain research programs. Such statements may be considered "forward-looking" within the meaning of the United States Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of words like "may," "will," "could," "should," "project," "believe," "anticipate," "expect," "plan," "estimate," "forecast," "potential," "intend," "continue" and variations of these words or comparable words. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Forward-looking statements include, but are not limited to, statements concerning our future expectations, plans, prospects and future operating results as well as projections of cash and marketable securities and sufficiency of funding for capital expenditures. Actual results may differ materially from those indicated by these forward-looking statements as a result of various factors including risks related to: our ability to secure regulatory approval for our products; our access to additional capital; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales and distribution of our products; our development of products; our ability to obtain and maintain patent protection for our discoveries and products; and our limited operating history; as well as those risks more fully discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-KSB filed with the SEC on April 2, 2007, and our other public documents filed with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date.
Cyberkinetics Contact:
Elizabeth A. Razee, 508-549-9981,
Ext. 109
Manager, Corporate Communications
erazee@cyberkinetics.com